ESTEVE expands into US market with acquisition of Regis Technologies

August 1, 2025
Mergers and Acquisitions Corporate, ESTEVE, Pharmacy, Regis Technologies, US pharma market, contract development and manufacturing organisation

ESTEVE (Esteve Química), based in Barcelona, Spain, has acquired Regis Technologies, a contract development and manufacturing organisation (CDMO) based in …

Richmond Pharmacology appoints Priscilla Ochuba as associate medical director

August 1, 2025
Research and Development Contract Research Organsation, Corporate, Pharmacy, Richmond Pharmacology, associate medical director

Richmond Pharmacology has announced the promotion of Priscilla Ochuba to associate medical director, effective 1 August 2025. The move recognises …

Labguru and Titian Software rebrand as Cenevo to accelerate connected labs

July 31, 2025
Analytical & Laboratory Services, Research and Development Cenevo, Corporate, Labguru, Laboratory management

Lab management companies, Labguru and Titian Software, have rebranded under a new unified name, Cenevo. This combines their solutions, Mosaic …

lab

Hansa Biopharma bolsters leadership team with new executive appointments

July 31, 2025
Research and Development Chief Human Resources Officer, Chief Legal Officer, Corporate, Executive Leadership Team, Hansa Biopharma, Vice President Corporate Affairs

Hansa Biopharma has announced three senior leadership appointments to support its global expansion as well as pre-commercial activities in the …

BioDuro and Atombeat partner to accelerate AI-powered peptide drug discovery

July 31, 2025
Mergers and Acquisitions AI, BioDuro, Corporate, Devices

BioDuro and Atombeat have announced a partnership to launch an artificial intelligence (AI)-driven platform designed to accelerate peptide drug discovery …

Key strategies to foster digital transformation in the NHS

July 30, 2025
Business Services, Market Access, Market Access Consultancy Corporate, Gateway to Local Adoption, NHS, Pharmacy, Visions4Health, digital transformation, pharmacy

In the third of the Gateway to Local Adoption series, Visions4Health caught up with James Scott, Digital and Informatics Specialist …

NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer

July 30, 2025
Medical Communications, Research and Development AstraZeneca, NHS, National Institute for Health and Care Excellence, Oncology, dual immunotherapy, hepatocellular carcinoma, liver cancer

AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence (NICE) for its dual immunotherapy …

laboratory-testing-az

Clinisys acquires Orchard Software to expand laboratory informatics leadership

July 30, 2025
Analytical & Laboratory Services, Mergers and Acquisitions, Research and Development Clinisys, Corporate, Francisco Partners, Orchard Software, laboratory informatics, laboratory information management systems

Clinisys has announced the acquisition of Orchard Software from Francisco Partners, strengthening its position in laboratory informatics. The strategic acquisition …

alzheimers_brain

Roche receives CE Mark for blood test to help rule out Alzheimer’s

July 30, 2025
Research and Development Alzheimer's disease, CE Mark approval, Eli Lilly, Neurology, Roche

Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in vitro diagnostic regulation-certified blood-based diagnostic …

europe-1395916_640

Sanofi’s Sarclisa gains EU approval for multiple myeloma treatment

July 30, 2025
Medical Communications, Research and Development European Commission, Oncology, Sanofi, Sarclisa, european union, multiple myeloma

Sanofi has received approval from the European Commission for the use of Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and …

Relief Therapeutics to merge with NeuroX to create AI-driven neurohealth company

July 29, 2025
Mergers and Acquisitions, Research and Development AI, Corporate, MindMaze, Neurology, Relief Therapeutics, neurological conditions

Relief Therapeutics has announced that it will combine with NeuroX Group, the successor to digital neurotherapeutics company MindMaze. The transaction …

Bristol Myers Squibb appoints Cristian Massacesi as chief medical officer and head of development

July 28, 2025
Research and Development Bristol Myer Squibb, Corporate, Executive Leadership Team, Head of Development, chief medical officer, executive vice president

Bristol Myers Squibb (BMS) has announced the appointment of Cristian Massacesi as executive vice president, chief medical officer, and head …

Neuraxpharm appoints Avendran Naidu as head of commercial upon launch of Australian affiliate

July 28, 2025
Manufacturing and Production, Research and Development Neuraxpharm, Neuraxpharm Australia, Neurology, central nervous system, multiple sclerosis

Neuraxpharm Group has announced the launch of Neuraxpharm Australia, furthering its global expansion beyond Europe and into key international markets. …

mental-health-3332122_960_720

Seaport Therapeutics doses first patient in trial of GlyphAllo for depression

July 25, 2025
Research and Development Psychiatry, Seaport Therapeutics, clinical trial, major depressive disorder, mental health, neuropsychiatric conditions

Seaport Therapeutics has dosed its first patient in its phase 2b BUOY-1 study of GlyphAllo (SPT-300), an oral prodrug of …

Cube Biotech appoints Michael Bencak as new CEO amid global expansion plans

July 25, 2025
Mergers and Acquisitions, Research and Development CEO, Corporate, Cube Biotech, IBA Lifescience, archimed, executive chairman

Cube Biotech has announced a leadership transition as the company continues its trajectory of global growth and innovation in protein …

PureTech Health appoints interim CEO Robert Lyne

July 24, 2025
Research and Development Corporate, PureTech Health, board of directors, chief portfolio officer, interim CEO

PureTech Health has announced the departure of chief executive officer (CEO) Bharatt Chowrira, who has stepped down from his role …

eyeimagenotext-1

OKYO Pharma reports promising phase 2 results for urcosimod in neuropathic corneal pain

July 24, 2025
Research and Development OKYO Pharma, Opthalmology, clinical trial, neuropathic corneal pain, ocular pain

OKYO Pharma has announced positive results from its phase 2 trial of urcosimod (formerly OK-101) in neuropathic corneal pain (NCP), …

The Gateway to Local Adoption Series

Latest content